Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/4/2025 | Buy → Neutral | Redburn Atlantic | |
2/19/2025 | $52.00 → $42.00 | Outperform → Neutral | Robert W. Baird |
1/6/2025 | $48.00 | Overweight → Equal-Weight | Morgan Stanley |
12/10/2024 | $42.50 → $54.00 | Hold → Buy | Jefferies |
10/17/2024 | $49.00 | Buy → Hold | HSBC Securities |
6/27/2024 | $50.00 | Peer Perform → Outperform | Wolfe Research |
12/19/2023 | $44.00 | Equal Weight | Wells Fargo |
12/13/2023 | Peer Perform | Wolfe Research |
Partnership designed to expand QIAGEN's leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for cancer research Combines QIAGEN's global reach and automation expertise with ID Solutions' assay development for research purposes and manufacturing strengths QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays and customized molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research applications. The combination of QIAGEN's glob
Acquisition adds Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases Strengthens QIAGEN Digital Insights offering for small and mid-sized labs worldwide with easy-to-use, fast and flexible NGS data interpretation in a rapidly growing market Franklin complements QCI Interpret, QCI Precision Insights and QIAGEN's leading genetic databases COSMIC and HGMD QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced it has signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests. The acquisition adds Franklin, Genoox's f
Supervisory Board intends to elect Stephen H. Rusckowski as Chairman following Annual General Meeting on June 26, 2025 Lawrence A. Rosen will not stand for re-election and will step down as Chairman and Supervisory Board member following Annual General Meeting on June 26, 2025 Prof. Dr. Elaine Mardis will also not stand for re-election after serving since 2014 All other current Supervisory Board members will stand for re-election to one-year terms QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board intends to elect Stephen H. Rusckowski to succeed Lawrence A. Rosen as Chairman of the Supervisory Board following its Annual General Me
LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its
BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. As CDO, Chan will play a key leadership role in advancing Actym's pipeline of first-in-class, systemically administered therapeutics that re-program the immunosuppressive microenvironment in solid tumors. Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer."Chan has significant experience advancing novel cancer
JERSEY, Channel Islands, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mohammad El Khoury as the Company's Chief Commercial Officer. In this role, Mr. El Khoury will oversee all commercial activities for the company as it continues to expand globally. "I am delighted to welcome a strong and experienced commercial leader like Mohammad to the Executive team. During the last 30 years, he has been partnering with customers across the globe. Mohammad will be instrumental in accelerating the commercialization of our MosaiQ solution. He will continue to build the commercial team and expand the distribution channels whil
SC 13G - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
SC 13G/A - QIAGEN N.V. (0001015820) (Subject)
Redburn Atlantic downgraded Qiagen from Buy to Neutral
Robert W. Baird downgraded Qiagen from Outperform to Neutral and set a new price target of $42.00 from $52.00 previously
Morgan Stanley downgraded Qiagen from Overweight to Equal-Weight and set a new price target of $48.00
Q1 2025 results confirm preliminary announcement: Net sales of $483 million (+5% actual rates, +7% constant exchange rates, CER); adjusted diluted EPS of $0.55 Net sales growth of +7% CER ahead of outlook for about +3% CER growth and adjusted diluted EPS of $0.56 CER ahead of outlook for at least $0.50 CER 29.8% adj. operating income margin up 4.1 percentage points vs. 25.7% in Q1 2024 Operating cash flow of $140 million in Q1 2025 vs. $133 million in Q1 2024 Proposal at Annual General Meeting to introduce a dividend as expansion of capital allocation strategy, also seek authorization for a new $500 million share repurchase Stephen H. Rusckowski proposed to become new Chairman
QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN's shareholders at the next Annual General Meeting scheduled for June 26, 2025. This milestone reflects QIAGEN's strategy to introduce a new avenue to increase shareholder returns while preserving flexibility to reinvest in long-term growth. The Supervisory Board's decision on the amended dividend policy and initial dividend payment is subject to approval by QIAGEN's shareholders. The initial dividend payment would consist of $0.25 per ordinary share. This proposal represents a total payout of a
QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, May 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 5803222 To avoid waiting time, please join the event conference 5-10 minute
SCHEDULE 13G/A - QIAGEN N.V. (0001015820) (Subject)
6-K - QIAGEN N.V. (0001015820) (Filer)
SCHEDULE 13G - QIAGEN N.V. (0001015820) (Subject)